June 9, 2022

Dalbavancin in Gram-positive periprosthetic joint infections

Key Points

Key points are not available for this paper at this time.

Abstract

Dalbavancin treatment for Gram-positive PJIs resulted in a similar outcome to SoC, with excellent safety and low rate of adverse effects. Dalbavancin seems to be a promising antimicrobial against PJIs by reducing the risk of Gram-positive re-infections and allowing a less frequent dosage with potential outpatient IV treatment.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Simon et al. (Thu,) studied this question.

synapsesocial.com/papers/69d8f983d2f7327e70ae4b0b https://doi.org/https://doi.org/10.1093/jac/dkac178

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies2011 · 11,982 citations
2The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria2018 · 2,100 citations
3Dalbavancin Dosage2018 · 2 citations
4Development and Validation of a Preoperative Surgical Site Infection Risk Score for Primary or Revision Knee and Hip Arthroplasty2016 · 48 citations
5A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation1987 · 50,100 citations

Perguntar à IA

Bookmark

View Full Paper